Business intelligence

We are working to centralize technology and partner-related data to improve decision-making that can address diagnostic gaps in low- and middle-income countries.

Business intelligence is a technology-driven process for gathering and analysing data, and delivering actionable information that helps us to make informed decision on technology, product and partner selection and engagement.

Our data-driven support focuses on different steps in the project lifecycle:

  • We coordinate a pre-concept process that aims at evaluating and prioritizing new ideas, to define which diagnostic technology and access solutions we should invest in. This process informs internal budget allocation to projects, supports resource mobilization discussions with partners and donors, and highlights new focus areas for our organization.
  • ​We manage technology and industry player scouting to support our project scoping and technology/partner identification. We share the outcomes of our landscapes through published reports and test directories, to empower external stakeholders including Ministries of Health, donors, other NGOs in their development, implementation, or guideline work
  • We manage industry partner selection and engagement, to help our organization choose the right partners, increase project success rate and optimize our investment. This includes coordination of the due diligence process of industry partners.

Our partnership approach

We work with partners to accelerate product development, bring transparency to the diagnostic market, and generate new data to inform decision-making at every level.

Technology reviews and evaluations

We are always on the look-out for innovative, new diagnostic solutions for poverty-related diseases that we can support on their journey from product development to market access and impact.

Test Directories

DxConnect test directories

FIND currently collates and manages directories of tests for COVID-19, Ebola, mpox, and neglected tropical diseases, to bring transparency to the diagnostic landscape.